Company Overview
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Why Investors Should Care
Generates a return on equity of 145.5%, reflecting efficient use of shareholder capital.
Revenue has grown at a 22.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $109.79M (+21.4% YoY); net profit $-153.49M.
- Trailing 12 Months Year-on-year growth — revenue +199.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 22.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 22.61% |
| 1 Year: | 199.20% |
Stock Price Performance
| 1 Year: | +119.24% |
| 6 Months: | +115.49% |
| 3 Months: | +64.21% |
| 1 Month: | -3.31% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)48.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 145.5%.
- Compounding revenue at 22.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | URGN UroGen Pharma Ltd. R2KR3KPHARMA | 44.09 | -21.72 | $2.15B | 0.00% | -81.06% | 145.53% | 22.61% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 481.00K | 364.00K | 283.00K | - | - | 18.00K | - | - | - | 372.00K | 3.46M | 7.49M | 13.03M | 11.35M | 13.56M | 16.60M | 16.10M | 17.19M | 21.14M | 20.85M | 23.53M | 18.78M | 21.85M | 25.20M | 24.57M | 20.25M | 24.21M | 27.48M | 50.96M | 72.46M |
| Gross Profit | - | - | - | - | 51.00K | 46.00K | -772.00K | - | - | 18.00K | - | - | - | 324.00K | 3.15M | 6.59M | 11.61M | 10.11M | 12.04M | 14.76M | 14.08M | 14.93M | 18.70M | 18.48M | 21.24M | 17.05M | 19.62M | 22.75M | 22.09M | 17.92M | 20.66M | 24.20M | 46.82M | 65.88M |
| Operating Income | -3.54M | -5.95M | -303.00K | -10.16M | -13.64M | -18.43M | -21.09M | -24.02M | -22.43M | -23.75M | -23.45M | -39.84M | -38.56M | -31.80M | -29.12M | -26.11M | -22.82M | -23.44M | -21.96M | -18.71M | -18.09M | -22.05M | -15.38M | -13.50M | - | -25.74M | -25.84M | -17.55M | - | -36.91M | -41.45M | -27.39M | -20.26M | 111.00K |
| Net Income | -3.42M | -6.20M | -298.00K | -10.09M | -13.38M | -18.03M | -20.53M | -23.72M | -21.44M | -22.48M | -22.25M | -38.97M | -37.79M | -31.35M | -28.82M | -25.93M | -26.22M | -30.21M | -28.39M | -26.69M | -25.83M | -30.21M | -24.14M | -21.88M | -26.02M | -32.29M | -33.40M | -23.67M | -37.51M | -43.84M | -49.94M | -33.35M | -23.57M | -14.35M |
| R&D Expense | - | - | - | - | - | 8.27M | 9.57M | - | 9.73M | 10.00M | 9.48M | - | 16.59M | 8.11M | 10.21M | 10.51M | 12.12M | 11.92M | 12.70M | 12.64M | 13.09M | 12.50M | 11.58M | 10.23M | - | 15.49M | 15.40M | 11.36M | - | 19.87M | 18.91M | 14.01M | 15.60M | 17.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.53M | 8.16M | 1.13M | 18.00K | 11.80M | 48.04M | 64.36M | 82.71M | 90.40M | 109.79M |
| Gross Profit | 17.50M | 7.56M | -675.00K | 18.00K | 10.79M | 42.88M | 56.70M | 73.35M | 81.52M | 97.34M |
| Operating Income | 798.00K | -19.95M | -77.18M | -109.48M | -126.74M | -92.29M | -79.04M | -65.54M | -96.78M | -124.86M |
| Net Income | -1.94M | -20.00M | -75.66M | -105.15M | -128.48M | -110.82M | -109.78M | -102.24M | -126.87M | -153.49M |
| R&D Expense | - | 18.70M | 36.93M | 49.30M | 47.31M | 47.64M | 52.91M | 45.61M | 57.15M | 67.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 75.55M | 103.56M | 202.39M | 122.00M | 119.75M | 135.62M | 178.31M | 285.71M | 200.46M |
| Total Equity | 16.28M | 16.31M | 68.52M | 90.09M | 180.30M | 96.36M | 8.41M | -89.36M | -65.21M | -8.80M | -105.47M |
| Cash & Equivalents | - | - | 37.00M | 101.32M | 49.69M | 52.86M | 44.36M | 55.41M | 95.00M | 171.99M | 110.75M |
| Long Term Debt | - | - | - | - | - | - | 0 | 97.54M | 98.55M | 121.73M | 122.21M |
| Total Liabilities | - | - | 7.04M | 13.46M | 22.09M | 25.65M | 111.33M | 224.98M | 243.52M | 294.51M | 305.93M |
| Current Liabilities | - | - | 7.04M | 13.46M | 19.48M | 21.44M | 22.38M | 23.92M | 31.21M | 45.95M | 46.42M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.19M | -9.57M | -37.33M | -71.02M | -105.89M | - | -87.56M | -76.38M | -96.77M | -162.44M |
| Investing Cash Flow | -719.00K | -36.28M | 35.29M | -145.59M | 93.24M | - | 1.06M | -953.00K | -20.61M | 61.56M |
| Financing Cash Flow | -9.00K | 61.59M | 66.42M | 165.25M | 16.53M | - | 97.13M | 116.93M | 194.62M | 39.92M |
| Capital Expenditure | -695.00K | -271.00K | -560.00K | -325.00K | -1.22M | - | -254.00K | -194.00K | -295.00K | -289.00K |
| Free Cash Flow | 3.49M | -9.84M | -37.89M | -71.34M | -107.10M | - | -87.81M | -76.57M | -97.06M | -162.73M |
| Net Change in Cash | - | - | - | - | - | - | 10.63M | 39.60M | 77.24M | -60.97M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 99.8% | 92.6% | -59.8% | 100.0% | 91.4% | 89.3% | 88.1% | 88.7% | 90.2% | 88.7% |
| Operating Margin % | 4.6% | -244.5% | -6,842.2% | -608,211.1% | -1,074.2% | -192.1% | -122.8% | -79.2% | -107.1% | -113.7% |
| Net Margin % | -11.1% | -245.2% | -6,707.2% | -584,144.4% | -1,088.9% | -230.7% | -170.6% | -123.6% | -140.4% | -139.8% |
| ROE % | -11.9% | -29.2% | -84.0% | -58.3% | -133.3% | -1,317.2% | 122.9% | 156.8% | 1,441.3% | 145.5% |
| ROCE % | - | -29.1% | -85.7% | -59.9% | -126.0% | -94.8% | -70.8% | -44.6% | -40.4% | -81.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RTW Investments LP | 9.30% | 4.54M | $198.20M |
| 2 | Blackrock Inc. | 6.55% | 3.20M | $139.65M |
| 3 | Morgan Stanley | 5.27% | 2.58M | $112.38M |
| 4 | Kynam Capital Management, LP | 4.98% | 2.43M | $106.18M |
| 5 | Jefferies Financial Group Inc. | 4.50% | 2.20M | $95.95M |
| 6 | SG Americas Securities, LLC | 4.20% | 2.05M | $89.55M |
| 7 | American Century Companies Inc | 3.45% | 1.69M | $73.53M |
| 8 | Acorn Capital Advisors, LLC | 3.42% | 1.67M | $72.99M |
| 9 | Point72 Asset Management, L.P. | 3.12% | 1.53M | $66.54M |
| 10 | Frontier Capital Management Company LLC | 3.09% | 1.51M | $65.80M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for URGN
UroGen will speak at three investor events in September - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOeUhXSWp0NVpfajZOMm5BNDNxVnp6VjVhN3FLX08yMTJhUTJObGlCMllZS29NUGo4R3JFR2FhdDhzSTRKUFVuclE3RkRrZ3JNN2RvcnBfX19mM1hsTVBkZnVTMWpqYVFCVmllaHZmWXNxYzJUajJHZHBhVHE3Z3piWFNjc3dGSzczbGwyaE…
URGN Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1jWFdPVGxfSkpSOEdfS1ZuU3BPLU4xaVZrdUtqTG1aUF9lUE9fY1pZRjliS0kyQzNuU015d2g5czBoUDUwVVdRLVp4WTkxU2QxSEtPbFN3WUhqcDlCMm9IN0VYYXA1U0dzdVMzcVRBQkoxSTNZLXpRTFBB?oc=5" target="_blank">URG…
$URGN stock is down 9% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQSi1GRGdPRXhHN0U3UkUtUkMxMTRHWXRnS3c5MTJNRExQNFNESnc0ZkJGQnpTZ3JMbFY1NGg3RjRZSVBXOGJwcUdSVF9JdndTcjRDZ0ZBdnBPRWFkR0pmYTBveUdacnFUOTdXSDVIUE9peVkwd2JQTjNHRXJzeS05R1R5NWpvbFhOZzZEeF…
UroGen Pharma Ltd (NASDAQ: URGN) Share Price, URGN Stock News, URGN Share Price & Updates - Kalkine
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE1uZTNJTldfVWl5S21sYVJPazRyY2p5ck5XWWNoQUJiOVUxYUJGMUpWMmRFM3FXVERWR1kxWVpjdUVxbWhnZjNDZTRydmhBNTJsZm5WUnln?oc=5" target="_blank">UroGen Pharma Ltd (NASDAQ: URGN) Share Price, URGN …
UroGen Pharma Ltd. Ordinary Shares (URGN) Stock Price Today: $43.64 - Gotrade
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE9RN3AzVFJIc0p0aGYtV2NSSTFueTBMRjF4dXh1WjBMcmxhWlN3RllEME5IZGR5RUhDYlo1d2Q2R21yME5pbVM5RmtadlFkd004Sy1rTWhtTQ?oc=5" target="_blank">UroGen Pharma Ltd. Ordinary Shares (URGN) Stock P…
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027 - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPTzNRdklZUFN2MjFrcTRTMVFZY244bzlWekZzX0doaE9yTkhENGk2MXI5dVh5SlJJdzFYWldzZnhReTY4dUtXcm9wR2x5Ym5VSXp5LTF4Vm92WU01dG1fYnFPTE9tMGxERmY2d1hpdGRqSXFwakdDdWVVS3Vhek1oc3BZX2x3UXFQZ19rNW…
URGN — Frequently Asked Questions
What is the current share price of UroGen Pharma Ltd. (URGN)?
As of 2026-09-07 16:24 PDT, UroGen Pharma Ltd. (URGN) trades at $44.09 on NasdaqGM. Its 52-week range is $16.42 to $50.29.
What is the market capitalisation of URGN?
UroGen Pharma Ltd. (URGN) has a market capitalisation of $2.15B on NasdaqGM.
What is the P/E ratio of URGN?
URGN trades at a trailing price-to-earnings (P/E) ratio of -21.72. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -18.41.
What is the return on equity (ROE) of URGN?
URGN has a return on equity (ROE) of 145.53%. Its return on capital employed (ROCE) is -81.06%.
Is URGN a good stock to buy?
This page provides a data-driven analysis of UroGen Pharma Ltd. (URGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.